The estimated Net Worth of Stephen Connelly is at least 3.66 百万$ dollars as of 6 October 2021. Dr Connelly owns over 8,092 units of Equillium Inc stock worth over 855,604$ and over the last 6 years he sold EQ stock worth over 2,286,000$. In addition, he makes 516,609$ as Chief Scientific Officer & Director at Equillium Inc.
Sign up
Dr D EQ stock SEC Form 4 insiders trading
Dr has made over 5 trades of the Equillium Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 8,092 units of EQ stock worth 33,663$ on 6 October 2021.
The largest trade he's ever made was selling 250,000 units of Equillium Inc stock on 13 July 2020 worth over 2,032,500$. On average, Dr trades about 29,543 units every 38 days since 2019. As of 6 October 2021 he still owns at least 995,467 units of Equillium Inc stock.
You can see the complete history of Dr Connelly stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Stephen Connelly Ph.D. biography
Dr. Stephen Connelly Ph.D. is the Chief Scientific Officer & Director at Equillium Inc.
What is the salary of Dr D?
As the Chief Scientific Officer & Director of Equillium Inc, the total compensation of Dr D at Equillium Inc is 516,609$. There are 4 executives at Equillium Inc getting paid more, with Krishna Polu having the highest compensation of 1,508,120$.
How old is Dr D?
Dr D is 39, he's been the Chief Scientific Officer & Director of Equillium Inc since . There are 16 older and 1 younger executives at Equillium Inc. The oldest executive at Equillium Inc is Bala Manian, 74, who is the Independent Director.
What's Dr D's mailing address?
Stephen's mailing address filed with the SEC is 2223 AVENIDA DE LA PLAYA, SUITE 105, , LA JOLLA, CA, 92037.
Insiders trading at Equillium Inc
Over the last 6 years, insiders at Equillium Inc have traded over 2,616,040$ worth of Equillium Inc stock. The most active insiders traders include Daniel Bradbury、Mark Pruzanski、Stephen Connelly. On average, Equillium Inc executives and independent directors trade stock every 95 days with the average trade being worth of 20,757$. The most recent stock trade was executed by Jason A Keyes on 16 July 2024, trading 10,000 units of EQ stock currently worth 8,700$.
What does Equillium Inc do?
equillium, inc., a clinical-stage biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor cd6, which is in phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and phase 1 clinical trial for the treatment of asthma and lupus nephritis. the company was formerly known as attenuate biopharmaceuticals, inc. and changed its name to equillium, inc. in may 2017. equillium, inc. was founded in 2017 and is headquartered in la jolla, california.
What does Equillium Inc's logo look like?
Complete history of Dr Connelly stock trades at Equillium Inc
Equillium Inc executives and stock owners
Equillium Inc executives and other stock owners filed with the SEC include:
-
Krishna Polu,
Executive Vice President - Research and Development, Chief Medical Officer -
Bruce Steel,
President, Chief Executive Officer, Director -
Daniel Bradbury,
Executive Chairman of the Board -
Dr. Krishna R. Polu,
Consultant -
Dr. Stephen Connelly Ph.D.,
Chief Scientific Officer & Director -
Bruce D. Steel C.F.A.,
Co-Founder, Pres, CEO & Director -
Stephen Connelly,
Chief Scientific Officer, Director -
Daniel Mark Bradbury,
Exec. Chairman -
Mark Pruzanski,
Independent Director -
Charles McDermott,
Independent Director -
Bala Manian,
Independent Director -
Martha Demski,
Independent Director -
Matthew Ritter,
Vice President - Corporate Development -
Maple Fung,
Vice President - Clinical Development -
Christine Zedelmayer,
Chief Operating Officer, Senior Vice President -
Jason Keyes,
Chief Financial Officer -
Jason A. Keyes,
Chief Financial Officer -
Dr. Dolca Thomas M.D.,
Exec. VP of R&D and Chief Medical Officer -
Joel M. Rothman,
Chief Devel. Officer -
Michael Moore,
VP of Investor Relations & Corp. Communications -
Christine Zedelmayer M.B.A., P.M.P.,
Sr. VP & COO -
Yu (Katherine) Xu,
-
Sa Biocon,
10% owner -
Dolca Thomas,
Chief Medical Officer -
Joel Rothman,
Chief Development Officer -
Barbara Troupin,